Literature DB >> 2114782

Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction.

G I Barbash1, A Roth, H Hod, H I Miller, M Modan, S Rath, Y H Zahav, A Shachar, S Basan, A Battler.   

Abstract

One hundred ninety patients with acute myocardial infarction (AMI) were treated with recombinant tissue-type plasminogen activator (rt-PA) 2.0 +/- 0.8 hours after the onset of symptoms. Eighty-seven patients were enrolled via mobile intensive care units and 103 through the emergency ward. Patients who were enrolled via the mobile intensive care units were randomized to immediate, prehospital treatment initiation, or to delayed, in-hospital treatment initiation. All 190 patients except 2 underwent delayed coronary angiography and, when indicated, angioplasty at 72 hours after enrollment. Patients treated within 2 hours and those treated 2 to 4 hours after symptom onset had similar preservation of left ventricular function, and similar prevalence of congestive heart failure at discharge. Patients treated within 2 hours of symptom onset had significantly lower short- (0.0 vs 6.3%, p = 0.01) and long-term (1.0 vs 9.5%, p = 0.03) mortality. Prehospital initiation of rt-PA appeared to be safe and feasible and resulted in a 40-minute decrease in the time from symptom onset to treatment initiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114782     DOI: 10.1016/0002-9149(90)90832-l

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Searching for the evidence in pre-hospital care: a review of randomised controlled trials. On behalf of the Ambulance Response Time Sub-Group of the National Ambulance Advisory Committee.

Authors:  H Brazier; A W Murphy; C Lynch; G Bury
Journal:  J Accid Emerg Med       Date:  1999-01

2.  Retrospective observational case-control study comparing prehospital thrombolytic therapy for ST-elevation myocardial infarction with in-hospital thrombolytic therapy for patients from same area.

Authors:  M S V M Chittari; I Ahmad; B Chambers; F Knight; A Scriven; D Pitcher
Journal:  Emerg Med J       Date:  2005-08       Impact factor: 2.740

Review 3.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 4.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

5.  Prehospital thrombolysis--calculated health benefit for catchment population of one hospital.

Authors:  Mark Kroese; David Kanka; Peter Weissberg; Barbara Arch; John Scott
Journal:  J R Soc Med       Date:  2004-05       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.